**Core tip:** Gadoxetic acid-enhanced-magnetic resonance imaging (EOB-MRI) has been shown to outperform other hepatocellular carcinoma (HCC) diagnostic tools. Our aim was to determine whether EOB-MRI findings could be used to predict pathologic stage T2 in patients with solitary HCC, clinical stage T1 (cT1). EOB-MRI was performed in 114 patients with solitary HCC \[39 with pathologic stage T2 (pT2) and 75 with pT1\]. Large tumor size, corona enhancement, and peritumoral hypointensity in hepatobiliary phase images were associated with high risk of pT2 HCC. The sensitivity of EOB-MRI for detecting pT2 HCC was 86.2% when two or three of these MRI features were present.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and its occurrence is highly related to hepatitis B and C virus infection. The TNM staging system of the American Joint Committee on Cancer seventh edition and Union for International Cancer Control defines T1 HCC as a solitary tumor without vascular invasion and defines T2 HCC as a solitary tumor with either gross or histologic involvement of vessels (microvascular or microscopic invasion)\[[@B1]\] or as multiple tumors (including satellite nodules), none more than 5 cm in greatest dimension. Therefore, clinical stage T1 (cT1) HCC on imaging studies can be either pathologic stage T1 or T2 (pT1 or pT2).

Methods of non-invasive prediction of pathologic stage of HCC, such as those using laboratory tests\[[@B2]\], have been investigated but not widely validated. Only a few imaging findings are widely accepted as prognostic biomarkers for HCC: tumor size, multifocal tumors, and vascular invasion\[[@B3]-[@B5]\]. The relative risk of HCC recurrence when patients present with macrovascular or microvascular invasion is 15- and 4.4-fold, respectively\[[@B6]\]. Patients with microvascular invasion or satellite nodules have higher rates of early and late recurrence and shorter overall survival after curative resection or liver transplantation\[[@B7]-[@B12]\]. Therefore, more extensive treatments, including wider surgical margin (if liver reserve is adequate) and more frequent follow-up examinations should be considered in such cases.

However, microvascular invasion and satellite nodules are difficult to detect preoperatively, even by current state-of-the-art imaging studies. Gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid (Gd-EOB-DTPA) is a commercially available hepatocyte-specific magnetic resonance (MR) contrast agent that on intravenous administration can enhance the contrast of the liver parenchyma\[[@B13]\]. Gd-EOB-DTPA can be added to conventional dynamic MR imaging (MRI) for hepatobiliary (HB) phase imaging. EOB-MRI outperforms dynamic contrast-enhanced computed tomography and other MRI techniques as a tool for establishing a diagnosis of HCC\[[@B14]-[@B16]\]. Kim *et al*\[[@B17]\] reported that detection of more HCCs by EOB-MRI improved overall survival of patients initially evaluated by computed tomography. However, unlike conventional MRI, which uses extracellular contrast agents, EOB-MRI has some limitations, such as weaker arterial enhancement, a narrower window of peak arterial enhancement, and severe respiratory motion artifacts in some cases\[[@B18]-[@B21]\]. Moreover, the usefulness of EOB-MRI for predicting the presence of microvascular invasion or satellite nodules has not yet been well established.

The purpose of our study is to investigate whether the imaging features of solitary HCC on preoperative EOB-MRI can be used to predict pT2 HCC and whether the finding of more than one aggressive imaging feature could increase the reliability of this prediction.

MATERIALS AND METHODS
=====================

Study population
----------------

This single-center retrospective study was conducted from January 2012 to December 2017. We retrospectively reviewed records from the pathology database in our institute. In total, 376 patients with HCC received liver resection and had pT1 or pT2. The criteria for inclusion were: First, newly diagnosed solitary HCC on preoperative imaging without obvious vascular invasion, lymphadenopathy, or extrahepatic metastasis; second, a preoperative Gd-EOB-DTPA MRI study; and third, no other treatment besides surgery. We excluded patients with recurrent HCC (*n* = 31), with combined tumors (intrahepatic cholangiocarcinoma) (*n* = 5), with no preoperative EOB-MRI study (*n* = 69), with only a preoperative computed tomography imaging study (*n* = 104), with ruptured HCC and hemoperitoneum (*n* = 4), undertaking other preoperative treatments (radiofrequency ablation, transarterial chemoembolization, intra-arterial infusion chemotherapy, and stereotactic radiosurgery) (*n* = 10), with no imaging study in our imaging archiving system (*n* = 1), with HCC on biopsy but only tumor necrosis postoperatively (*n* = 2), with two HCCs on EOB-MRI (clinical stage T2) (*n* = 28), and receiving segmentectomy limited to removal of only one tumor due to poor liver reserve (*n* = 8) (Figure [1](#F1){ref-type="fig"}).

![Flow chart of the study population selection process and the inclusion and exclusion criteria. HCC: Hepatocellular carcinoma; EOB-MRI: ethoxybenzyl magnetic resonance imaging; CT: Computed tomography.](WJG-25-2636-g001){#F1}

Methods
-------

We used Gd-EOB-DTPA (Primovist^®^, Bayer Healthcare, Berlin, Germany) as MRI contrast agent for these patients. Bolus injection of 10 mL of Gd-EOB-DTPA at the rate of 1 mL/s was immediately followed by a normal saline flush of 10-20 mL. In order to optimize hepatic arterial-phase timing, MRI was performed by using a 1.5-T system (Avanto, Siemens Healthineers, Erlangen, Germany) with 32 independent RF channels or another 1.5-T system (Aera, Siemens Healthineers) with 64 independent RF channels and body coils. A rectangular field of view of 32 cm × 24 cm to 29 cm × 22 cm was tailored for each patient.

The standard liver MRI protocol in our hospital consisted of a respiration-triggered fat-saturated T2-weighted fast spin-echo or turbo spin-echo sequence \[repetition time (TR), 4175 ms; echo time (TE), 76 ms; acceleration factor, 2; number of excitation, 1; slice thickness, 5 mm\], double-echo T1-weighted gradient-echo sequence (in-phase: TR, 164 ms; TE 4.76 ms; opposed-phase: TR, 164; TE 2.38 ms; acceleration factor, 2; number of excitation, 1; slice thickness, 5 mm), and a dynamic contrast-enhanced T1-weighted gradient-echo sequence with chemically selective fat suppression. The dynamic contrast-enhanced 3D MRI was performed using a volumetric interpolated breath-hold examination sequence (TR, 4.45 ms; TE, 1.60  ms; flip angle, 10° for arterial to transitional phase, 30° for HB phase; acceleration factor, 2; number of excitation, 1; slice thickness, 3 mm) with bolus-tracking protocol. Image acquisition began with the volumetric interpolated breath-hold examination sequence (arterial phase) and was initiated when the contrast medium was visible at the level of the celiac trunk of the abdominal aorta. We also acquired images of the portal venous phase at about 60-70 seconds, transitional phase at about 3 minutes, and HB phase at 20 min after the start of contrast medium injection. Diffusion-weighted imaging (with b values as 50, 400, and 800 s/mm^2^) was performed using a respiratory-triggered single-shot echo-planar imaging sequence; then an apparent diffusion coefficient map was generated.

Characteristic MRI features
---------------------------

We measured the largest outer-edge-to-outer-edge dimension of the tumor including the capsule in the HB phase according to version 2017 of the Liver Imaging Reporting and Data System of the American College of Radiology\[[@B22]\]. The following imaging features were examined: hyperintensity in unenhanced T2-weighted images, hypointensity in unenhanced T1-weighted images, arterial enhancement, corona enhancement, washout appearance, capsular appearance, hypointensity in the tumor tissue during the HB phase, peritumoral hypointensity in the HB phase, hypointense rim in the HB phase, intratumoral fat, hyperintensity on diffusion-weighted imaging, hypointensity on apparent diffusion coefficient map, mosaic appearance, nodule-in-nodule appearance, and the margin (smooth or irregular)\[[@B3],[@B14],[@B23]-[@B29]\]. Corona enhancement was defined according to the Liver Imaging Reporting and Data System version 2017 as an uneven area of hyper-enhancement surrounding the hypervascular HCC in the late arterial phase or early portal venous phase. Peritumoral hypointensity in the HB phase was defined as irregular, wedge-shaped or a ﬂame-like ring of enhancement surrounding the tumor and outside of the tumor margin usually with a lower intensity than liver parenchyma but a higher intensity than the tumor\[[@B27]\]. According to the Liver Imaging Reporting and Data System version 2017, the hypointense rim formed a discrete boundary between the tumor and its surroundings. Presence or absence of these findings in each individual set of images was recorded by two radiologists independently. Discrepancies were resolved by consensus.

Pathology evaluation
--------------------

The pathology was analyzed by experienced pathologists after the surgery. The macroscopic and microscopic characteristics of the resected specimen included: Number and size of the HCC nodules, degree of histologic differentiation of HCC, status of microvascular invasion, presence or absence of satellite nodules, presence or absence of tumor necrosis, capsule formation with or without disruption, and stage of background liver parenchyma fibrosis. Microvascular invasion was identified on microscopic examination as tumor emboli in endothelial cell-lined vascular spaces. Satellite nodules were detected on microscopic examination as small HCCs separated from the main HCC by tumor-free liver parenchyma\[[@B8]\].

Statistical analysis
--------------------

Continuous variables are presented as mean and standard deviation and were analyzed statistically with the Student *t*-test. Categorical variables are presented as frequency and percentage and were analyzed with the Pearson chi-square test or Fisher exact test. The association (measured by odds ratio) of pathologic stage T2 HCC with all selected potential risk factors was assessed using univariate logistic regression analysis. In addition, the diagnostic accuracy of imaging findings for predicting pathologic stage T2 HCC was assessed using the ROC curve. SAS 9.4 for Windows (SAS Institute, Cary, NC, United States) and Prism 6 (GraphPad Software Inc., La Jolla, CA, United States) were used to perform these analyses. Statistical significance was considered as *P* \< 0.05.

RESULTS
=======

There was no significant difference in age, gender, hepatitis virus type, serum tumor biomarkers (alpha-fetoprotein and CA19-9), interval between imaging and surgery, and METAVIR score of liver fibrosis between the pT1 and pT2 groups (Table [1](#T1){ref-type="table"}).

###### 

Comparison of demographic and other characteristics between the pathologic stage T2 and T1 groups, *n* (%)

  **Characteristics**                                            **pT2, *n* = 39**   **pT1, *n* = 75**   ***P* value**
  -------------------------------------------------------------- ------------------- ------------------- ---------------
  Age, mean ± SD                                                 60.54 ± 11.17       58.32 ± 10.95       0.3101
  Gender                                                                             0.375               
  Male                                                           26 (66.7)           57 (76.0)           
  Female                                                         13 (33.3)           18 (24.0)           
  Hepatitis virus subtype                                                                                
  HBV                                                            21 (53.8)           50 (66.7)           0.223
  HCV                                                            15 (38.5)           21 (28.0)           0.292
  HBV and HCV                                                    3 (7.7)             3 (4.0)             0.385
  Tumor marker                                                                                           
  AFP                                                            415.3 ± 1536.1      812.3 ± 5922.0      0.5683
  CA-19-9                                                        116.2 ± 606.2       14.1 ± 15.6         0.2998
  Interval between the dates of imaging and surgery, mean ± SD   17.69 ± 30.80       18.09 ± 20.58       0.9419
  METAVIR score of liver fibrosis                                                    0.7852              
  F0-F3                                                          28 (71.79)          52 (69.33)          
  F4                                                             11 (28.21)          23 (30.67)          

HBV and HCV: Hepatitis viruses B and C; AFP: Alpha-fetoprotein; CA-19-9: Cancer antigen 19-9; pT1: Pathologic stage T1; pT2: Pathologic stage T2.

There were 114 patients included in our study (75 with pT1 HCC and 39 with pT2 HCC). In the pT2 group, 28 patients had a tumor with microvascular invasion, eight had a tumor with one or more satellite nodules, and three had a tumor with both microvascular invasion and one or more satellite nodules (Figure [1](#F1){ref-type="fig"}).

Regarding the imaging features, there was no significant between-group difference in T2 hyperintensity, T1 hypointensity, arterial enhancement, washout appearance, capsular appearance, hypointensity in the HB phase, intratumoral fat, hyperintensity on diffusion-weighted imaging, hypointensity on the apparent diffusion coefficient map, mosaic appearance, and the margin (smooth or irregular). Fourteen patients (35.9%) in the pT2 group and 13 patients (17.3%) in the pT1 group showed corona enhancement, with an odds ratio of 2.671 and 95% confidence interval (CI) of 1.101-6.480 (*P* = 0.030). HCCs with this imaging feature were more likely to be stage pT2. We also noted differing tendencies for peritumoral hypointensity to occur in the HB phase between the pT2 group (*n* = 16; 41.0%) and pT1 group (*n* = 18; 24%), with an odds ratio of 2.203 and 95%CI of 0.961-5.049 (*P* = 0.062), suggesting HCCs with this imaging feature also tend to be stage pT2 tumors (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

###### 

Imaging characteristics compared between the pathologic stage T2 group and T1 group, *n* (%)

  **Characteristics**                         **pT2, *n* = 39**   **pT1, *n* = 75**   ***P* value**
  ------------------------------------------- ------------------- ------------------- ---------------
  T2 hyperintensity                           37 (94.9)           68 (90.7)           0.716
  T1 hypointensity                            35 (89.7)           69 (92.0)           0.733
  Arterial enhancement                        38 (97.4)           70 (93.3)           0.662
  Corona enhancement                          14 (35.9)           13 (17.3)           0.037
  Washout appearance                          36 (92.3)           69 (92.0)           1.000
  Capsular appearance                         14 (35.9)           38 (50.7)           0.167
  Hypointensity of tumor in the HB phase      37 (94.9)           74 (98.7)           0.269
  Peritumoral hypointensity in the HB phase   16 (41.0)           18 (24.0)           0.084
  Hypointense-rim in the HB phase             5 (12.8)            21 (28.0)           0.099
  Intratumoral fat                            8 (20.5)            18 (24.0)           0.815
  Hyperintensity on DWI                       39 (100.0)          72 (96.0)           0.550
  Hypointensity on ADC map                    16 (41.0)           32 (42.7)           1.000
  Mosaic architecture                         27 (69.2)           48 (64.0)           0.679
  Margin type                                                                         0.503
  Smooth                                      27 (69.2)           57 (76.0)           
  Irregular                                   12 (30.8)           18 (24.0)           
  AJCC v.7                                    39 (100.0)          75 (100.0)          
  AJCC v.8                                                                            0.005
  cT1a (≤ 2 cm)                               3 (7.7)             24 (32.0)           
  cT1b (\> 2 cm)                              36 (92.3)           51 (68.0)           

HB: Hepatobiliary; DWI: Diffusion weighted imaging; ADC: Apparent diffusion coefficient; AJCC: American Joint Committee on Cancer; pT1: Pathologic stage T1; pT2: Pathologic stage T2.

![Images in a 73-year-old woman with a solitary hepatocellular carcinoma (tumor size 2.6 cm) in segment VI. A and B: Axial view of T2- and T1-weighted magnetic resonance images with fat suppression before administration of gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid; C: Arterial phase and D: Portal venous phase showing hyperenhancing mass in segment VI with washout appearance, which is the typical appearance of hepatocellular carcinoma, as well as corona enhancement (arrow); E: Hepatobiliary phase, axial view of T1-weighted three-dimensional gradient-echo magnetic resonance image with fat suppression. The faint low signal intensity around the tumor is the peritumoral hypointensity (arrow); F: The tumor is identifiable postoperatively as a pT2 hepatocellular carcinoma because a satellite nodule surrounds the main tumor.](WJG-25-2636-g002){#F2}

###### 

The odds ratios for imaging features favoring a diagnosis of pathologic stage T2 over pT1

  **Features**                             **Crude OR**   **95%CI**        ***P* value**
  ---------------------------------------- -------------- ---------------- ---------------
  T2 hyperintensity                        1.904          (0.376-9.639)    0.436
  T1 hypointensity                         0.761          (0.201-2.874)    0.687
  Arterial enhancement                     2.714          (0.306-24.085)   0.370
  Corona enhancement                       2.671          (1.101-6.480)    0.030
  Washout appearance                       1.043          (0.246-4.419)    0.954
  Capsular appearance                      0.545          (0.246-1.208)    0.135
  Hypointensity of tumor in the HB phase   0.250          (0.022-2.847)    0.264
  Peritumoral hypointensity in HB phase    2.203          (0.961-5.049)    0.062
  Hypointense-rim in the HB phase          0.378          (0.130-1.098)    0.074
  Intratumoral fat                         0.817          (0.319-2.093)    0.674
  Mosaic architecture                      1.266          (0.553-2.895)    0.577
  Hyperintensity on DWI                    N/A            N/A              N/A
  Hypointensity ADC map                    0.935          (0.426-2.050)    0.866
  Tumor margin                                                             
  Smooth (baseline)                                                        
  Non-smooth                               1.407          (0.594-3.333)    0.437
  AJCC v.8                                                                 
  cT1a (baseline)                          1.00           Reference        
  cT1b                                     6.727          (1.483-30.517)   0.014

Because all patients in the study group demonstrated hyperintensity on diffusion weighted imaging, we were not able to calculate the odds ratio and *P* value. HB: Hepatobiliary; DWI: Diffusion weighted imaging; ADC: Apparent diffusion coefficient; AJCC: American Joint Committee on Cancer; pT1: Pathologic stage T1; pT2: Pathologic stage T2; OR: Odds ratio; CI: Confidence interval.

![Images in a 64-year-old man with a solitary hepatocellular carcinoma (tumor size 5.5 cm) in segment VIII. A and B: Axial view of T2- and T1-weighted magnetic resonance images with fat suppression before administration of gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid; C: Arterial phase and D: Portal venous phase showing hyperenhancing mass in segment VIII with partial washout appearance and corona enhancement (arrow); E: Subtracted images of the portal venous phase with more obvious corona enhancement; F: Hepatobiliary phase, T1-weighted three-dimensional gradient-echo magnetic resonance image (axial view) with fat suppression. The obvious flame-like peritumoral hypointensity (arrow) is noted. This tumor was identified postoperatively as a pT2 hepatocellular carcinoma owing to its microvascular invasion.](WJG-25-2636-g003){#F3}

Three patients (7.7%) in the pT2 group and 24 patients (32%) in the pT1 had tumors smaller than or equal to 2 cm, with an odds ratio of 0.149 and 95%CI of 0.033-0.674 (*P* = 0.013). Tumors smaller or equal to 2 cm in diameter tended to be stage pT1. The occurrence of another HB phase imaging feature, *i.e*., the hypointense rim, differed between the pT2 group (*n* = 5, 12.8%) and pT1 group (*n* = 21, 28%), with an odds ratio of 0.378 and 95%CI of 0.130-1.098 (*P* = 0.074), indicating that HCC with this imaging feature tends to be stage pT1 (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Images in a 65-year-old woman with a solitary hepatocellular carcinoma (tumor size 2.1 cm) in segment VII. A and B: Axial view of T2- and T1-weighted magnetic resonance images with fat suppression before administration of gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid; C: Arterial phase showing hyperenhancing mass in segment VII; D: Portal venous phase with notable washout appearance of the hepatocellular carcinoma; E: Hepatobiliary phase, axial view of T1-weighted three-dimensional gradient-echo magnetic resonance image with fat suppression. The hypointense rim (arrow) is noted. Postoperatively, pT1 hepatocellular carcinoma was diagnosed.](WJG-25-2636-g004){#F4}

![Images in a 60-year-old man with a solitary hepatocellular carcinoma (tumor size 5.5 cm) in segment VII. A and B: Axial view of T2- and T1-weighted magnetic resonance images with fat suppression before administration of gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid; C: Arterial phase. Note the hyperenhancing hepatocellular carcinoma in segment VII; D: Portal venous phase. Note the capsular appearance (arrow) of the hepatocellular carcinoma; E: Hepatobiliary phase, axial view of T1-weighted three-dimensional gradient-echo magnetic resonance image with fat suppression. The tumor has an obvious hypointense rim (arrow). pT1 hepatocellular carcinoma was diagnosed postoperatively.](WJG-25-2636-g005){#F5}

In our study using the Youden index, the optimal cut-point of tumor size was 2.3 cm. The area under the ROC curve (not shown) was 0.5745, which was not good enough for pT2 HCC prediction based only on tumor size. Other imaging findings suggesting pT2 in our study were corona enhancement and peritumoral hypointensity in the HB phase. Tumors had an odds ratio for being stage pT2 of 1.037 (95%CI: 0.285-3.766) in the presence of one aggressive feature (*i.e*., tumor size larger than 2.3 cm in diameter, corona enhancement, or peritumoral hypointensity). The odds ratio further increased to 6.25 (95%CI 1.788-21.845) in the presence of two or three aggressive features. The sensitivity of EOB-MRI for detecting pT2 HCC was 86.2% (25/29) when the HCCs had two or three of these MRI features (Table [4](#T4){ref-type="table"}).

###### 

Logistic regression estimates of odds ratios for pathologic stage T2 hepatocellular carcinoma in patients with solitary tumor on Gd-EOB-DTPA-enhanced magnetic resonance imaging

  **Combinations of aggressive features**   **Number of pT2 patients**   **OR (95%CI)**
  ----------------------------------------- ---------------------------- ----------------------
  A = 0 and B = 0 and C = 0                 4                            Reference
  Only A or Only B or Only C                10                           1.037 (0.285-3.766)
  A + B or B + C or A + C or A + B + C      25                           6.250 (1.788-21.845)

Gd-EOB-DTPA: Gadolinium ethoxybenzyl diethylene-triaminepentaacetic acid; A = 0: Tumor size \< 2.3 cm; B = 0: No peritumoral hypointensity on hepatobiliary phase; C = 0: No corona enhancement; A: Tumor size ≥ 2.3 cm; B: Presence of peritumoral hypointensity on hepatobiliary phase; C: Presence of corona enhancement; OR: Odds ratio; CI: Confidence interval.

Large HCCs (size ≥ 2.3 cm) tended to be pT2, but in the absence of corona enhancement or peritumoral hypointensity in the HB phase, a significant number of them were pT1. Large HCCs with a hypointense rim were less likely to be pT2 (odds ratio = 0.26; 95%CI: 0.0086-0.7810; *P* = 0.016) than large HCCs without this feature. Small HCCs (less than 2.3 cm) tended to be pT1 lesions, were likely to be pT2 in the presence of aggressive imaging features on EOB-MRI (odds ratio: 34.00; 95%CI: 3.251-355.6; *P* = 0.0006), and were pT1 in the presence of an HB phase hypointense rim. Large HCCs with aggressive imaging features and without hypointense rims were most likely to be pT2 lesions (Figure [6](#F6){ref-type="fig"}).

![Solitary hepatocellular carcinomas on gadoxetic acid-enhanced magnetic resonance imaging. Large (≥ 2.3 cm) (A) and small (\< 2.3 cm) (B) solitary hepatocellular carcinomas (HCCs) with aggressive imaging findings tend to be stage pT2 tumors (*P* \< 0.001). Large (≥ 2.3 cm) HCCs with hypointense rims on MRI in the HB phase tend to be a stage pT1 tumors (*P* = 0.0155); C: Large HCCs with aggressive imaging features are more likely to be stage pT2 tumors if a hypointense rim is absent rather than present in the hepatobiliary phase; D: HCC: Hepatocellular carcinoma; HB: Hepatobiliary; pT1: Pathologic stage T1; pT2: Pathologic stage T2.](WJG-25-2636-g006){#F6}

DISCUSSION
==========

In our study, tumor size and the "aggressive" imaging features corona enhancement and peritumoral hypointensity tended to predict the pathologic stage of solitary HCC as pT2. However, tumor size alone was not a good predictor.

Tumor size is an important factor affecting the incidence of occult vascular invasion and advanced histologic grade in HCC. The incidence of microscopic vascular invasion increases with tumor size\[[@B5]\]. However, there is still no consensus about the best tumor cutoff size to predict microinvasion. The odds ratio for HCC with microvascular invasion was 7.1 (95%CI: 2.6-19.8) when preoperative tumor size was ≥ 5 cm in the study by Kaibori *et al*\[[@B30]\] and 3 (95%CI: 1.2-7.1) when tumor size was greater than 4 cm in the study by Esnaola *et al*\[[@B31]\]. In our study, the tumor cutoff size (measured on MRI) was 2.3 cm, which was close to that proposed by the American Joint Committee on Cancer\[[@B32],[@B33]\].

Corona enhancement and peritumoral hypointensity were also considered as predictive factors of microvascular invasion in a study conducted by Miyata *et al*\[[@B34]\]. Satellite nodules were found to occur more commonly when HCC invades adjacent vessels\[[@B35],[@B36]\]. Our results support these previous findings and are consistent with other previous studies showing greater micro-metastasis occurrence in areas of coronal enhancement\[[@B37],[@B38]\].

The cause of peritumoral hypointensity on HB phase images is still not clear. One possibility is that tumor microinvasion into small portal branches results in hemodynamic and perfusion changes. Perfusion change may be associated with change in the levels of organic anion-transporting polypeptide and multidrug-resistant protein expressed on hepatocytes\[[@B27],[@B39]\]. Our findings are consistent with the study conducted by Kim *et al*\[[@B27]\], which identified peritumoral hypointensity in the HB phase of EOB-MRI as a predictor of HCC microvascular invasion.

The imaging features with predictive value might also reflect tumor biology. Previous studies have shown that during hepatocarcinogenesis the arterial supply system gradually shifts from intranodular portal to intranodular arterial, and the venous drainage system shifts from hepatic venous to hepatic sinusoidal and then to portal venous\[[@B40]\]. These changes are observable on MRI studies. We found that regardless of size, tumors were more likely to be pT2 lesions when corona enhancement and peritumoral hypointensity are present in the HB phase. However, the relationship between these two features remains unclear. In our study, not all HCCs had both corona enhancement in the arterial/portal phase and peritumoral hypointensity in the HB phase. These features might reflect different stages of hepatocarcinogenesis. Further studies are mandatory to confirm this hypothesis. Nevertheless, identifying these imaging findings before treatment might have clinical implications, particularly because many HCCs can now be diagnosed based on typical imaging findings and be treated with local ablation techniques, such as radio-frequency ablation\[[@B41],[@B42]\].

The hypointense rim in the HB phase was not only an ancillary feature favoring diagnosis of HCC over other malignancies in a previous study\[[@B22]\], but also a relatively "protective" imaging biomarker in our study. Even large HCCs with hypointense rim in the HB phase tended to be pT1 lesions (*P* = 0.0155). In our study, hypointense rim might also have had a protective effect in patients with a large HCC in the presence of aggressive imaging features. In previous studies, the prognosis of encapsulated HCC was considered to be better than that of more advanced HCC but worse than that of non-encapsulated HCC diagnosed at an earlier stage of hepatocellular carcino-genesis\[[@B43]\].

The tumor margin status of HCCs is controversial. Kim *et al*\[[@B44]\] concluded from univariate analysis but not multivariate analysis that non-smooth tumor margin is a risk factor for microvascular invasion. However, the odds ratio for smooth *versus* non-smooth tumor margin was not significantly different between the pT1 and pT2 groups in our study. Our findings are consistent with the results of Chandarana *et al*\[[@B45]\] who identified tumor multifocality on MRI and not tumor margin as the predictor of microvascular invasion.

A capsule or pseudocapsule is indicated by the presence of a "hypointense rim in the HB phase." However, one study concluded that the "capsule appearance" as indicated by HB phase hypointense rim could improve capsule detection\[[@B28]\]. This may explain why no significant difference in "capsule appearance" was found between the pT1 and pT2 groups in our study. In previous studies on HCCs, a better prognosis was indicated by the presence rather than the absence of a capsule\[[@B46],[@B47]\]. Witjes *et al*\[[@B48]\] reported a greater frequency of microvascular invasion in those with enhanced capsular appearance on enhanced MR images than in those without it. This might also indicate a histological difference between the "capsule appearance" on dynamic contrast-enhanced MRI study and the presence of hypointense rim in the HB phase of EOB-MRI.

Limitations
-----------

Our study had some limitations. First, our study was a single-institute study with a relatively small sample size. Second, selection bias could not be avoided because of the retrospective nature of our study design. In it, the radiologists evaluating these features were blind to pathologic stage but not pathologic diagnosis. Prospective studies with larger population sizes should be performed to further validate our findings. Third, the time interval between MRI and surgery was about 18 d, and tumor progression during this interval may have confounded our correlation analysis between MRI and pathology. Fourth, because insurance reimbursement was an issue, we did not adjust contrast medium dose according to the body weight of each patient. This might affect the appearance of MR images. In addition, because prognosis was not assessed in this study, we did not determine whether these EOB-MRI imaging features could be used as biomarkers to predict clinical outcome.

CONCLUSION
==========

Tumor size is an important prognostic factor, but in and of itself not good enough for classifying a single HCC lesion as pT1 or pT2 preoperatively. Imaging features of EOB-MRI might be useful to further stratify patients with solitary HCC. A large solitary HCC with corona enhancement and peritumoral hypointensity in the HB phase tends to be pT2, particularly in the absence of HB phase hypointense rim.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Higher pathologic stage of HCC has higher risk of recurrence and shorter survival. However, accurate prediction of pathologic stage from current pre-treatment imaging features is still difficult.

Research motivation
-------------------

Modern magnetic resonance imaging (MRI) techniques using tissue-specific contrast agents provide many imaging features. We hypothesize that these imaging features may help to determine or predict pathologic stage of HCC.

Research objectives
-------------------

To analyze the relationship between imaging features and the pathologic stage of HCC.

Research methods
----------------

There were 114 patients \[75 with pathologic stage T1 (pT1) HCC and 39 with pathologic stage T2 (pT2) HCC\] in this study. We reviewed each patient's imaging features on preoperative gadoxetic acid-enhanced (EOB) MRI. These included: hyperintensity in unenhanced T2-weighted images, hypointensity in unenhanced T1-weighted images, arterial enhancement, corona enhancement, washout appearance, capsular appearance, hypointensity in the tumor tissue during the hepatobiliary (HB) phase, peritumoral hypointensity in the HB phase, hypointense rim in the HB phase, intratumoral fat, hyperintensity on diffusion-weighted imaging, hypointensity on apparent diffusion coefficient map, mosaic appearance, nodule-in-nodule appearance, and the margin. All of these patients underwent surgery and sections of their tumor specimens were analyzed microscopically by an experienced pathologist. Univariate and multivariate analyses were performed to identify predictors of microvascular invasion or satellite nodules.

Research results
----------------

We found that large tumor size (≥ 2.3 cm) and two MR findings, *i.e*., corona enhancement \[odds ratio = 2.67; 95% confidence interval: 1.101-6.480) and peritumoral hypointensity in HB phase images (odds ratio = 2.203; 95% confidence interval: 0.961-5.049) were associated with high risk of pT2 HCC. The positive likelihood ratio was 6.25 (95% confidence interval: 1.788-21.845) and sensitivity of EOB-MRI for detecting pT2 HCC was 86.2% when two or three of these MRI features were present. Small tumor size and hypointense rim in the HB phase were regarded as benign features. Small HCCs with hypointense rim but not associated with aggressive features were mostly pT1 lesions (specificity, 100%).

Research conclusion
-------------------

Imaging features on EOB-MRI could potentially be used to predict the pathologic stage of solitary HCC as pT1 or pT2.

Research perspectives
---------------------

Imaging biomarkers of HCC are not yet well established. This study further identified imaging features of EOB-MRI that can be used to predict pathologic stage. This should be further validated in prospective studies. Research should be carried out to determine whether these MRI biomarkers help improve the clinical outcome of patients with HCC.
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